Identification	O
and	O
characterization	O
of	O
the	O
novel	O
Col10a1	O
regulatory	O
mechanism	O
during	O
chondrocyte	O
hypertrophic	O
differentiation	O
.	O


The	O
majority	O
of	O
human	O
skeleton	O
develops	O
through	O
the	O
endochondral	O
pathway	O
,	O
in	O
which	O
cartilage	O
-	O
forming	O
chondrocytes	O
proliferate	O
and	O
enlarge	O
into	O
hypertrophic	O
chondrocytes	O
that	O
eventually	O
undergo	O
apoptosis	O
and	O
are	O
replaced	O
by	O
bone	O
.	O


Although	O
at	O
a	O
terminal	O
differentiation	O
stage	O
,	O
hypertrophic	O
chondrocytes	O
have	O
been	O
implicated	O
as	O
the	O
principal	O
engine	O
of	O
bone	O
growth	O
.	O


Abnormal	O
chondrocyte	O
hypertrophy	O
has	O
been	O
seen	O
in	O
many	O
skeletal	O
dysplasia	O
and	O
osteoarthritis	O
.	O


Meanwhile	O
,	O
as	O
a	O
specific	O
marker	O
of	O
hypertrophic	O
chondrocytes	O
,	O
the	O
type	O
X	O
collagen	O
gene	O
(	O
COL10A1	O
)	O
is	O
also	O
critical	O
for	O
endochondral	O
bone	O
formation	O
,	O
as	O
mutation	O
and	O
altered	O
COL10A1	O
expression	O
are	O
often	O
accompanied	O
by	O
abnormal	O
chondrocyte	O
hypertrophy	O
in	O
many	O
skeletal	O
diseases	O
.	O


However	O
,	O
how	O
the	O
type	O
X	O
collagen	O
gene	O
is	O
regulated	O
during	O
chondrocyte	O
hypertrophy	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O


We	O
have	O
recently	O
demonstrated	O
that	O
Runx2	O
interaction	O
with	O
a	O
150	B-ENHANCER
-	I-ENHANCER
bp	I-ENHANCER
mouse	I-ENHANCER
Col10a1	I-ENHANCER
cis	I-ENHANCER
-	I-ENHANCER
enhancer	E-ENHANCER
is	O
required	O
but	O
not	O
sufficient	O
for	O
its	O
hypertrophic	O
chondrocyte	O
-	O
specific	O
reporter	O
expression	O
in	O
transgenic	O
mice	O
,	O
suggesting	O
requirement	O
of	O
additional	O
Col10a1	O
regulators	O
.	O


In	O
this	O
study	O
,	O
we	O
report	O
in	O
silico	O
sequence	O
analysis	O
of	O
this	O
150	B-ENHANCER
-	I-ENHANCER
bp	I-ENHANCER
enhancer	E-ENHANCER
and	O
identification	O
of	O
its	O
multiple	O
binding	O
factors	O
,	O
including	O
AP1	O
,	O
MEF2	O
,	O
NFAT	O
,	O
Runx1	O
and	O
TBX5	O
.	O


Using	O
this	O
enhancer	S-ENHANCER
as	O
bait	O
,	O
we	O
performed	O
yeast	O
one	O
-	O
hybrid	O
assay	O
and	O
identified	O
multiple	O
candidate	O
Col10a1	O
-	O
interacting	O
genes	O
,	O
including	O
cyclooxygenase	O
1	O
(	O
Cox	O
-	O
1	O
)	O
and	O
Cox	O
-	O
2	O
.	O


We	O
have	O
also	O
performed	O
mass	O
spectrometry	O
analysis	O
and	O
detected	O
EF1	O
-	O
alpha	O
,	O
Fus	O
,	O
GdF7	O
and	O
Runx3	O
as	O
components	O
of	O
the	O
specific	O
complex	O
formed	O
by	O
the	O
cis	B-ENHANCER
-	I-ENHANCER
enhancer	E-ENHANCER
and	O
nuclear	O
extracts	O
from	O
hypertrophic	O
MCT	O
(	O
mouse	O
chondrocytes	O
immortalized	O
with	O
large	O
T	O
antigen	O
)	O
cells	O
that	O
express	O
Col10a1	O
abundantly	O
.	O


Notably	O
,	O
some	O
of	O
the	O
candidate	O
genes	O
are	O
differentially	O
expressed	O
in	O
hypertrophic	O
MCT	O
cells	O
and	O
have	O
been	O
associated	O
with	O
chondrocyte	O
hypertrophy	O
and	O
Runx2	O
,	O
an	O
indispensible	O
Col10a1	O
regulator	O
.	O


Intriguingly	O
,	O
we	O
detected	O
high	O
-	O
level	O
Cox	O
-	O
2	O
expression	O
in	O
hypertrophic	O
MCT	O
cells	O
.	O


Electrophoretic	O
mobility	O
shift	O
assay	O
and	O
chromatin	O
immunoprecipitation	O
assays	O
confirmed	O
the	O
interaction	O
between	O
Cox	O
-	O
2	O
and	O
Col10a1	B-ENHANCER
cis	I-ENHANCER
-	I-ENHANCER
enhancer	E-ENHANCER
,	O
supporting	O
its	O
role	O
as	O
a	O
candidate	O
Col10a1	O
regulator	O
.	O


Together	O
,	O
our	O
data	O
support	O
a	O
Cox	O
-	O
2	O
-	O
containing	O
,	O
Runx2	O
-	O
centered	O
Col10a1	O
regulatory	O
mechanism	O
,	O
during	O
chondrocyte	O
hypertrophic	O
differentiation	O
.	O
